Cite

HARVARD Citation

    Miller, R. et al. (n.d.). 2022-RA-1276-ESGO Pembrolizumab monotherapy for advanced clear cell gynaecological cancer: phase II PEACOCC trial. International journal of gynecological cancer. p. A316. [Online]. 
  
Back to record